Amogastrin for the 99mTc-pertechnetate imaging of the gastric mucosa.
Most of the gastric diseases seat in the mucosa, and the present investigation was undertaken in order to see if amogastrin, a synthetic tetrapeptide, was capable of enhancing gastric accretion of intravenous 99mTc pertechnetate in man as well as in the rabbit. Improvement of gastric scintigraphy was achievable with a pretreatment of the agent by increasing the gastric accretion and reducing the background radioactivity in the liver and small intestinum.